A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Inclusion Criteria: * Age 18 years and older * Subjects must have a documented positive test for the SARS-CoV-2 infection within 7 days of randomization * Subject must be hospitalized within 72 hours of randomization * Subjects must be receiving standard of care for SARS-CoV-2 * Subject/Legally Authorized Representative (LAR) must have the ability to understand and give informed consent * Subject must be able to take and absorb hydroxychloroquine at the discretion of the investigator Exclusion Criteria: * Prior receipt of hydroxychloroquine for treatment or prophylaxis of SARS-CoV-2 or patient is taking hydroxychloroquine for other approved indications (e.g., lupus, rheumatoid arthritis) * No documented SARS-CoV-2 infection * Mechanical ventilation * Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives Preexisting retinopathy documented in medical history * Pregnancy or Breastfeeding * Concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins (rifampin, rifabutin) * Antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide) * History of glucose-6-phosphate dehydrogenase deficiency * Pre-treatment corrected QT interval (QTc) \>500 milliseconds * Pressor requirement to maintain blood pressure * Alanine aminotransferase (ALT) and/or asparate aminotransferase (AST) level \> 5X upper limit of normal * Creatinine clearance \<30 mL/min or requirement of dialysis or continuous venovenous hemofiltration * Concomitant participation in a therapeutic trial for SARS-CoV-2 or receiving any experimental treatment for SARS-CoV-2 within 7 days of randomization * Any condition that in the opinion of the principal investigator would prevent participation in the trial or would interfere with the trial endpoints